Future of HIV/AIDS Care in Low- and Middle- Income Countries

  • Christopher J. Hoffmann
  • Lisa A. Mills
  • Joel E. Gallant


Viral Load Virologic Failure Immune Reconstitution Inflammatory Syndrome Active Case Finding Structure Treatment Interruption 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Alimonti, J.B., Ball, T.B. & Fowke, K.R. (2003). Mechanisms of CD4+ T lymphocyte cell death in human immunodeficiency virus infection and AIDS. The Journal of General Virology, 84, 1649–1661.PubMedGoogle Scholar
  2. Arendt, V., Ndimubanza, P., Vyankandondera, J., Ndayisaba, G., Muganda, J., Courteille, O., Rutanga, C., Havuga, E., Dhont, E., Mujawamassiga, A., Omes, C. & Peltier, A. (2007). AMATA study: effectiveness of antiretroviral therapy in breastfeeding mothers to prevent post-natal vertical transmission in Rwanda. Presented at the 4th IAS Conference, July 2007, Sydney, Australia (Abstract TUAX102).Google Scholar
  3. Arici, C., Ripamonti, D., Maggiolo, F., Rizzi, M., Finazzi, M.G., Pezzotti, P. & Suter, F. (2002). Factors associated with the failure of HIV-positive persons to return for scheduled medical visits. HIV Clinical Trials, 3, 52–57.PubMedGoogle Scholar
  4. Ayele, W., Schuurman, R., Messele, T., Dorigo-Zetsma, W., Mengistu, Y., Goudsmit, J., Paxton, W.A., de Baar, M.P. & Pollakis, G. (2007). Use of dried spots of whole blood, plasma, and mother's milk collected on filter paper for measurement of human immunodeficiency virus type 1 burden. Journal of Clinical Microbiology, 45, 891–896.PubMedGoogle Scholar
  5. Badri, M., Cleary, S., Maartens, G., Pitt, J., Bekker, L.G., Orrell, C. & Wood, R. (2006a). When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study. Antiviral Therapy, 11, 63–72.Google Scholar
  6. Badri, M., Lawn, S.D. & Wood, R. (2006b). Short-term risk of AIDS or death in people infected with HIV-1 before antiretroviral therapy in South Africa: a longitudinal study. Lancet, 368, 1254–1259.Google Scholar
  7. Basenero, A., Castelnuovo, B., Birabwa, E., John L., MacAdam, K., Schlech, W. & Kambugu, A. (2007). Inadequacy of clinical and immunological criteria in identifying virologic failure of 1st line ART: the Ugandan experience. Presented at the 4th IAS Conference, July 2007, Sydney, Australia (Abstract WEAB102).Google Scholar
  8. Bangsberg, D.R. (2006). Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clinical Infectious Diseases, 43, 939–941.PubMedGoogle Scholar
  9. Bangsberg, D.R., Acosta, E.P., Gupta, R., Guzman, D., Riley, E.D., Harrigan, P.R., Parkin, N. & Deeks, S.G. (2006). Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS, 20, 223–231.PubMedGoogle Scholar
  10. Bartlett, J.G. & Gallant, J.E. (2007). Medical management of HIV infection. Johns Hopkins Medicine Health Publishing Business Group, Baltimore.Google Scholar
  11. Behforouz, H.L., Farmer, P.E. & Mukherjee, J.S. (2004). From directly observed therapy to accompagnateurs: enhancing AIDS treatment outcomes in Haiti and in Boston. Clinical Infectious Diseases, 38 Suppl 5, S429–S436.PubMedGoogle Scholar
  12. Bell, D.J., Kapitao, Y., Sikwese, R., van Oosterhout, J.J. & Lalloo, D.G. (2007). Adherence to antiretroviral therapy in patients receiving free treatment from a Government hospital in Blantyre, Malawi. Journal of Acquired Immune Deficiency Syndromes, 45, 560–563.PubMedGoogle Scholar
  13. Boehme, C., Molokova, E., Minja, F., Geis, S., Loscher, T., Maboko, L., Koulchin, V. & Hoelscher, M. (2005). Detection of mycobacterial lipoarabinomannan with an antigen-capture ELISA in unprocessed urine of Tanzanian patients with suspected tuberculosis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 99, 893–900.PubMedGoogle Scholar
  14. Bolhaar, M.G. & Karstaedt, A.S. (2007). A high incidence of lactic acidosis and symptomatic hyperlactatemia in women receiving highly active antiretroviral therapy in Soweto, South Africa. Clinical Infectious Diseases, 45, 254–260.PubMedGoogle Scholar
  15. Braitstein, P., Brinkhof, M.W., Dabis, F., Schechter, M., Boulle, A., Miotti, P., Wood, R., Laurent, C., Sprinz, E., Seyler, C., Bangsberg, D.R., Balestr, E., Sterne, J.A., May, M. & Egger, M. (2006). Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet, 367, 817–824.PubMedGoogle Scholar
  16. Bucher, H.C., Griffith, L.E., Guyatt, G.H., Sudre, P., Naef, M., Sendi, P. & Battegay, M. (1999). Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. AIDS, 13, 501–507.PubMedGoogle Scholar
  17. Calmy, A., Pinoges, L., Szumilin, E., Zachariah, R., Ford, N. & Ferradini, L. (2006). Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. AIDS, 20, 1163–1169.PubMedGoogle Scholar
  18. Campo, R.E., Lalanne, R., Tanner, T.J., Jayaweera, D.T., Rodriguez, A.E., Fontaine, L. & Kolber, M.A. (2005). Lopinavir/ritonavir maintenance monotherapy after successful viral suppression with standard highly active antiretroviral therapy in HIV-1-infected patients. AIDS, 19, 447–449.PubMedGoogle Scholar
  19. Castro, A. (2005). Adherence to antiretroviral therapy: merging the clinical and social course of AIDS. PLoS Medicine, 2, e338.PubMedGoogle Scholar
  20. Chang, L.W., Kagaayi, J., Nakigozi, G., Packer, A., Serwadda, D., Quinn, T.C., Gray R.H., Reynolds, S.J., Bollinger, R. (2007) Evaluation of a pilot cluster-randomized mobile phone intervention used by peer health workers in a rural antiretroviral care program in Rakai, Uganda. Presented at the 4th IAS Conference, July 2007, Sydney, Australia (Abstract WEPEB104).Google Scholar
  21. Chesney, M. (2003). Adherence to HAART regimens. AIDS Patient Care and STDS, 17, 169–177.PubMedGoogle Scholar
  22. Clarke, S.M., Mulcahy, F.M., Tjia, J., Reynolds, H.E., Gibbons, S.E., Barry, M.G. & Back, D.J. (2001). The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. British Journal of Clinical Pharmacology, 51, 213–217.PubMedGoogle Scholar
  23. Coghlan, M.E., Sommadossi, J.P., Jhala, N.C., Many, W.J., Saag, M.S. & Johnson, V.A. (2001). Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases. Clinical Infectious Diseases, 33, 1914–1921.PubMedGoogle Scholar
  24. Connor, E.M., Sperling, R.S., Gelber, R., Kiselev, P., Scott, G., O'Sullivan, M.J., VanDyke, R., Bey, M., Shearer, W., Jacobson, R.L., Jimenez, E., O'Neill, E., Bazin, B., Delfraissy, J.-F., Culnane, M., Coombs, R., Elkins, M., Moye, J., Stratton, P. & Balsley, J. (1994). Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. New England Journal of Medicine, 331, 1173–1180.PubMedGoogle Scholar
  25. Coovadia, H. (2004). Antiretroviral agents – how best to protect infants from HIV and save their mothers from AIDS. New England Journal of Medicine, 351, 289–292.PubMedGoogle Scholar
  26. Coovadia, H.M., Rollins, N.C., Bland, R.M., Little, K., Coutsoudis, A., Bennish, M.L. & Newell, M.L. (2007). Mother-to-child transmission of HIV-1 infection during exclusive breastfeeding in the first 6 months of life: an intervention cohort study. Lancet, 369, 1107–1116.PubMedGoogle Scholar
  27. Corbett, E.L., Bandason, T., Cheung, Y.B., Munyati, S., Godfrey-Faussett, P., Hayes, R., Churchyard, G., Butterworth, A. & Mason, P. (2007). Epidemiology of tuberculosis in a high HIV prevalence population provided with enhanced diagnosis of symptomatic disease. PLoS Medicine 4, e22.PubMedGoogle Scholar
  28. Corbett, E.L., Marston, B., Churchyard, G.J. & De Cock, K.M. (2006). Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment. Lancet, 367, 926–937.PubMedGoogle Scholar
  29. Corbett, E.L., Steketee, R.W., ter Kuile, F.O., Latif, A.S., Kamali, A. & Hayes, R.J. (2002). HIV-1/AIDS and the control of other infectious diseases in Africa. Lancet, 359, 2177–2187.PubMedGoogle Scholar
  30. Creek, T.L., Ntumy, R., Seipone, K., Smith, M., Mogodi, M., Smit, M., Legwaila, K., Molokwane, I., Tebele, G., Mazhani, L., Shaffer, N. & Kilmarx, P.H. (2007). Successful introduction of routine opt-out HIV testing in antenatal care in Botswana. Journal of Acquired Immune Deficiency Syndromes, 45, 102–107.PubMedGoogle Scholar
  31. d'Arminio, M.A., Sabin, C.A., Phillips, A., Sterne, J., May, M., Justice, A., Dabis, F., Grabar, S., Ledergerber, B., Gill, J., Reiss, P. & Egger, M. (2005). The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Archives of Internal Medicine, 165, 416–423.Google Scholar
  32. Danel, C., Moh, R., Anzian, A., Abo, Y., Chenal, H., Guehi, C., Gabillard, D., Sorho, S., Rouet, F., Eholie, S. & Anglaret, X. (2006a). Tolerance and acceptability of an efavirenz-based regimen in 740 adults in West Africa. Journal of Acquired Immune Deficiency Syndromes, 42, 29–35.Google Scholar
  33. Danel, C., Moh, R., Minga, A., Anzian, A., Ba-Gomis, O., Kanga, C., Nzunetu, G., Gabillard, D., Rouet, F., Sorho, S., Chaix, M.L., Eholie, S., Menan, H., Sauvageot, D., Bissagnene, E., Salamon, R. & Anglaret, X. (2006b). CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in West Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet, 367, 1981–1989.Google Scholar
  34. DART Virology Group and Trial Team. (2006). Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS, 20, 1391–1399.Google Scholar
  35. Day, J.H., Miyamura, K., Grant, A.D., Leeuw, A., Munsamy, J., Baggaley, R. & Churchyard, G.J. (2003). Attitudes to HIV voluntary counselling and testing among mineworkers in South Africa: will availability of antiretroviral therapy encourage testing? AIDS Care, 15, 665–672.PubMedGoogle Scholar
  36. Derache, A., Traore, O., Koita, V., Sylla, A., Tubiana, R., Simon, A., Canestri, A., Carcelain, G., Katlama, C., Calvez, V., Cisse, M. & Marcelin, A.G. (2007). Genetic diversity and drug resistance mutations in HIV type 1 from untreated patients in Bamako, Mali. Antiviral Therapy, 12, 123–129.PubMedGoogle Scholar
  37. Detsika, M.G., Chandler, B., Khoo, S.H., Winstanley, C., Cane, P., Back, D.J. & Owen, A. (2007). Detection and quantification of minority HIV isolates harbouring the D30N mutation by real-time PCR amplification. Journal of Antimicrobial Chemotherapy, 60, 881–884.PubMedGoogle Scholar
  38. Dieye, T.N., Vereecken, C., Diallo, A.A., Ondoa, P., Diaw, P.A., Camara, M., Karam, F., Mboup, S. & Kestens, L. (2005). Absolute CD4 T-cell counting in resource-poor settings: direct volumetric measurements versus bead-based clinical flow cytometry instruments. Journal of Acquired Immune Deficiency Syndromes, 39, 32–37.PubMedGoogle Scholar
  39. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. (2006). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. www.aidsinfo.nih.gov (Accessed October 10, 2006).
  40. Eholie, S.P., Tanon, A., Polneau, S., Ouiminga, M., Djadji, A., Kangah-Koffi, C., Diakite, N., Anglaret, X., Kakou, A. & Bissagnene, E. (2007). Field adherence to highly active antiretroviral therapy in HIV-infected adults in Abidjan, Cote d'Ivoire. Journal of Acquired Immune Deficiency Syndromes, 45, 355–358.PubMedGoogle Scholar
  41. Espert, L., Denizot, M., Grimaldi, M., Robert-Hebmann, V., Gay, B., Varbanov, M., Codogno, P. & Biard-Piechaczyk, M. (2006). Autophagy is involved in T cell death after binding of HIV-1 envelope proteins to CXCR4. Journal of Clinical Investigation, 116, 2161–2172.PubMedGoogle Scholar
  42. Fabiani, M., Cawthorne, A., Nattabi, B., Ayella, E.O., Ogwang, M. & Declich, S. (2007). Investigating factors associated with uptake of HIV voluntary counselling and testing among pregnant women living in North Uganda. AIDS Care, 19, 733–739.PubMedGoogle Scholar
  43. Farmer, P., Leandre, F., Mukherjee, J., Gupta, R., Tarter, L. & Kim, J.Y. (2001). Community-based treatment of advanced HIV disease: introducing DOT-HAART (directly observed therapy with highly active antiretroviral therapy). Bulletin of the World Health Organization, 79, 1145–1151.PubMedGoogle Scholar
  44. Fauci, A.S., Pantaleo, G., Stanley, S. & Weissman, D. (1996). Immunopathogenic mechanisms of HIV infection. Annals of Internal Medicine, 124, 654–663.PubMedGoogle Scholar
  45. Ferradini, L., Jeannin. A., Pinoges, L., Izopet, J., Odhiambo, D., Mankhambo, L., Karungi, G., Szumilin, E., Balandine, S., Fedida, G., Carrieri, M.P., Spire, B., Ford, N., Tassie, J.M., Guerin, P.J. & Brasher, C. (2006). Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet, 367, 1335–1342.PubMedGoogle Scholar
  46. Finzi, D., Hermankova, M., Pierson, T., Carruth, L.M., Buck, C., Chaisson, R.E., Quinn, T.C., Chadwick, K., Margolick, J., Brookmeyer, R., Gallant, J., Markowitz, M., Ho, D.D., Richman, D.D. & Siliciano, R.F. (1997). Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science, 278, 1295–1300.PubMedGoogle Scholar
  47. Gallant, J.E. (2007). Drug resistance after failure of initial antiretroviral therapy in resource-limited countries. Clinical Infectious Diseases, 44, 453–455.PubMedGoogle Scholar
  48. Gallant, J.E., DeJesus, E., Arribas, J.R., Pozniak, A.L., Gazzard, B., Campo, R.E., Lu, B., McColl, D., Chuck, S., Enejosa, J., Toole, J.J. & Cheng, A.K. (2006). Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. New England Journal of Medicine, 354, 251–260.PubMedGoogle Scholar
  49. Gandhi, N.R., Moll, A., Sturm, A.W., Pawinski, R., Govender, T., Lalloo, U., Zeller, K., Andrews, J., Friedland, G. (2006). Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368, 1575–1580.PubMedGoogle Scholar
  50. Geddes, R., Knight, S., Moosa, M.Y., Reddi, A., Uebel, K. & Sunpath, H. (2006). A high incidence of nucleoside reverse transcriptase inhibitor (NRTI)-induced lactic acidosis in HIV-infected patients in a South African context. South African Medical Journal, 96, 722–724.PubMedGoogle Scholar
  51. Getahun, H., Harrington, M., O'Brien, R. & Nunn, P. (2007). Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings. Lancet, 369, 2042–2049.PubMedGoogle Scholar
  52. Golub, J.E., Saraceni, V., Cavalcante, S.C., Pacheco, A.G., Moulton, L.H., King, B.S., Efron, A., Moore, R.D., Chaisson, R.E. & Durovni, B. (2007). The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS, 21, 1441–1448.PubMedGoogle Scholar
  53. Haggerty, C.M., Pitt, E. & Siliciano, R.F. (2006). The latent reservoir for HIV-1 in resting CD4+ T cells and other viral reservoirs during chronic infection. Current Opinion in HIV and AIDS, 1, 62–68.PubMedGoogle Scholar
  54. Hammer, S.M., Saag, M.S., Schechter, M., Montaner, J.S., Schooley, R.T., Jacobsen, D.M., Thompson, M.A., Carpenter, C.C., Fischl, M.A., Gazzard, B.G., Gatell, J.M., Hirsch, M.S., Katzenstein, D.A., Richman, D.D., Vella, S., Yeni, P.G. & Volberding, P.A. (2006). Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. Journal of the American Medical Association, 296, 827–843.PubMedGoogle Scholar
  55. Hanna, G.J. & Hirsch, M.S. (2005). Antiretroviral therapy for human immunodeficiency virus infection. In: Principles and practice of infectious diseases (eds. Mandell, G.L., Bennet, J.E. & Dolin, R.). Elsevier, Philadelphia, pp. 1655–1679.Google Scholar
  56. Hirsch, H.H., Kaufmann, G., Sendi, P. & Battegay, M. (2004). Immune reconstitution in HIV infected patients. Clinical Infectious Diseases, 38, 1159–1166.PubMedGoogle Scholar
  57. Hoffmann, C.J., Charalambous, S., Puso, T., Fielding, K.L., Martin, D., Innes, C., Churchyard, G.J., Chaisson, R.E. & Grant, A.D. (2006). The impact of timing of regimen change on outcomes during ART failure in Africa. Presented at the XVI International AIDS Conference, August 2006, Toronto, Canada (Abstract THPE0124).Google Scholar
  58. Hoffmann, C.J., Charalambous, S., Thio, C.L., Martin, D.J., Pemba, L., Fielding, K.L., Churchyard, G.J., Chaisson, R.E. & Grant, A.D. (2007). Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS, 21, 1301–1308.PubMedGoogle Scholar
  59. Hoffmann, C.J. & Thio, C.L. (2007). Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infectious Diseases, 7, 402–409.PubMedGoogle Scholar
  60. Holkova, B., Takeshita, K., Cheng, D.M., Volm, M., Wasserheit, C., Demopoulos, R. & Chanan-Khan, A. (2001). Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi's sarcoma treated with chemotherapy. Journal of Clinical Oncology, 19, 3848–3851.PubMedGoogle Scholar
  61. Hosseinipour, M., van Oosterhout, J., Weigel, R., Mzigangira, D., Saukila, N., Mhango, B., Phiri, R., Phiri, S., & Kumwenda, J. (2007). Validating clinical and immunological definitions of antiretroviral treatment failure in Malawi. Presented at the 4th IAS Conference, July 2007, Sydney, Australia (Abstract WEAB101).Google Scholar
  62. Hughes, A.R., Mosteller, M., Bansal, A.T., Davies, K., Haneline, S.A., Lai, E.H., Nangle, K., Scott, T., Spreen, W.R., Warren, L.L. & Roses, A.D. (2004). Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics, 5, 203–211.PubMedGoogle Scholar
  63. Karcher, H., Omondi, A., Odera, J., Kunz, A. & Harms, G. (2007). Risk factors for treatment denial and loss to follow-up in an antiretroviral treatment cohort in Kenya. Tropical Medicine and International Health, 12, 687–694.PubMedGoogle Scholar
  64. Kebaabetswe, P.M. (2007). Barriers to participation in the prevention of mother-to-child HIV transmission program in Gaborone, Botswana a qualitative approach. AIDS Care, 19, 355–360.PubMedGoogle Scholar
  65. Kisenge, P.R., Hawkins, A.T., Maro, V.P., McHele, J.P., Swai, N.S., Mueller, A. & Houpt, E.R. (2007). Low CD4 count plus coma predicts cryptococcal meningitis in Tanzania. BMC Infectious Diseases, 7, 39.PubMedGoogle Scholar
  66. Koenig, S.P., Leandre, F., Farmer, P.E. (2004). Scaling-up HIV treatment programmes in resource-limited settings: the rural Haiti experience. AIDS. Suppl 3, S21–S25.Google Scholar
  67. Laeyendecker, O., Li, X., Arroyo, M., McCutchan, F., Gray, R., Wawer, M., Serwadda, D., Nalugoda, F., Kigozi, G. & Quinn, T. (2006). The effect of HIV subtype on rapid disease progression in Rakai, Uganda. Presented at the 13th Conference on Retroviruses and Opportunistic Infections, February 2006, Denver, Colorado (Abstract 44LB).Google Scholar
  68. Lanoy, E., Mary-Krause, M., Tattevin, P., Dray-Spira, R., Duvivier, C., Fischer, P., Obadia, Y., Lert, F. & Costagliola, D. (2006). Predictors identified for losses to follow-up among HIV-seropositive patients. Journal of Clinical Epidemiology, 59, 829–835.PubMedGoogle Scholar
  69. Lawn, S.D., Myer, L., Bekker, L.G. & Wood, R. (2006). Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS, 20, 1605–1612.PubMedGoogle Scholar
  70. Lawn, S.D., Myer, L., Bekker, L.G. & Wood, R. (2007). Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS, 21, 335–341.PubMedGoogle Scholar
  71. Lewden, C., Chene, G., Morlat, P., Raffi, F., Dupon, M., Dellamonica, P., Pellegrin, J.L., Katlama, C., Dabis, F. & Leport, C. (2007). HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. Journal of Acquired Immune Deficiency Syndromes 46, 72–77PubMedGoogle Scholar
  72. Lockman, S., Shapiro, R.L., Smeaton, L.M., Wester, C., Thior, I., Stevens, L., Chand, F., Makhema, J., Moffat, C., Asmelash, A., Ndase, P., Arimi, P., van Widenfelt, E., Mazhani, L., Novitsky, V., Lagakos, S. & Essex, M. (2007). Response to antiretroviral therapy after a single, peripartum dose of nevirapine. New England Journal of Medicine, 356, 135–147.PubMedGoogle Scholar
  73. Lohse, N., Hansen, A.B., Pedersen, G., Kronborg, G., Gerstoft, J., Sorensen, H.T., Vaeth, M. & Obel, N. (2007). Survival of persons with and without HIV infection in Denmark, 1995–2005. Annals of Internal Medicine, 146, 87-95.PubMedGoogle Scholar
  74. Lucas, G.M., Mullen, B.A., Weidle, P.J., Hader, S., McCaul, M.E. & Moore, R.D. (2006). Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groups. Clinical Infectious Diseases, 42, 1628–1635.PubMedGoogle Scholar
  75. Male circumcision for HIV prevention: research implications for policy and programming. WHO/UNAIDS technical consultation, 6–8 March 2007. Conclusions and recommendations. (2007). Reproductive Health Matters, 15, 11–14.Google Scholar
  76. Manosuthi, W., Sungkanuparph, S., Thakkinstian, A., Rattanasiri, S., Chaovavanich, A., Prasithsirikul, W., Likanonsakul, S. & Ruxrungtham, K. (2006). Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin. Clinical Infectious Diseases, 43, 253–255.PubMedGoogle Scholar
  77. Manzi, M., Zachariah, R., Teck, R., Buhendwa, L., Kazima, J., Bakali, E., Firmenich, P. & Humblet, P. (2005). High acceptability of voluntary counselling and HIV-testing but unacceptable loss to follow up in a prevention of mother-to-child HIV transmission programme in rural Malawi: scaling-up requires a different way of acting. Tropical Medicine and International Health, 10, 1242–1250.PubMedGoogle Scholar
  78. Marconi, V.C., Sunpath, H., Lu Z., Gordon, M., Koranteng, K., Hampton, J., Ross, D., Losina, E., Walker, B. & Kuritzkes, D. (2007). Prevalence of HIV-1 drug resistance after virologic failure of first HAART regimen in South Africa: initial results of the South Africa resistance cohort study. Presented at the 14th Conference on Retroviruses and Opportunistic Infections, February 2007, Los Angeles, USA (Abstract 94).Google Scholar
  79. Marks, G., Crepaz, N. & Janssen, R.S. (2006). Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. AIDS, 20, 1447–1450.PubMedGoogle Scholar
  80. Martin, A.M., Nolan, D., Gaudieri, S., Almeida, C.A., Nolan, R., James, I., Carvalho, F., Phillips, E., Christiansen, F.T., Purcell, A.W., McCluskey, J. & Mallal, S. (2004). Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proceedings of the National Academy of Sciences U S A, 101, 4180–4185.Google Scholar
  81. Matovu, J.K., Gray, R.H., Makumbi, F., Wawer, M.J., Serwadda, D., Kigozi, G., Sewankambo, N.K. & Nalugoda, F. (2005). Voluntary HIV counseling and testing acceptance, sexual risk behavior and HIV incidence in Rakai, Uganda. AIDS, 19, 503–511.PubMedGoogle Scholar
  82. Mbanya, D., Assah, F., Ndembi, N. & Kaptue, L. (2007). Monitoring antiretroviral therapy in HIV/AIDS patients in resource-limited settings: CD4 counts or total lymphocyte counts? International Journal of Infectious Diseases, 11, 157–160.PubMedGoogle Scholar
  83. Mellors, J.W., Rinaldo, C.R., Jr., Gupta, P., White, R.M., Todd, J.A. & Kingsley, L.A. (1996). Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science, 272, 1167–1170.PubMedGoogle Scholar
  84. Mermin, J., Bunnell, R., Lule, J., Opio, A., Gibbons, A., Dybul, M. & Kaplan, J. (2005). Developing an evidence-based, preventive care package for persons with HIV in Africa. Tropical Medicine and International Health, 10, 961–970.PubMedGoogle Scholar
  85. Mermin, J., Ekwaru, J.P., Liechty,. C.A., Were, W., Downing, R., Ransom, R., Weidle, P., Lule, J., Coutinho, A. & Solberg, P. (2006). Effect of co-trimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study. Lancet, 367, 1256–1261.PubMedGoogle Scholar
  86. Mfinanga, G.S., Mutayoba, B., Mbogo, G., Kahwa, A., Kimaro, G., Mhame, P.P., Mwangi, C., Malecela, M.N. & Kitua, A.Y. (2007). Quality of HIV laboratory testing in Tanzania: a situation analysis. Tanzania Health Research Bulletin, 9, 44–47.PubMedGoogle Scholar
  87. Micol, R., Lortholary, O., Sar, B., Laureillard, D., Ngeth, C., Dousset, J.P., Chanroeun, H., Ferradini, L., Guerin, P.J., Dromer, F. & Fontanet, A. (2007). Prevalence, determinants of positivity, and clinical utility of cryptococcal antigenemia in Cambodian HIV-Infected patients. Journal of Acquired Immune Deficiency Syndromes 45, 555–559PubMedGoogle Scholar
  88. Mills, E.J., Nachega, J.B., Buchan, I., Orbinski, J., Attaran, A., Singh, S., Rachlis, B., Wu, P., Cooper, C., Thabane, L., Wilson, K., Guyatt, G.H. & Bangsberg, D.R. (2006). Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. Journal of the American Medical Association, 296, 679–690.PubMedGoogle Scholar
  89. Mills, L.A., Kagaayi, J., Galiwango, R.M., Nalugoda, F., Bwanika, J.B., Ouma, J., Gray, R.L., Wawer, M.J., Quinn, T.C., Serwadda, D., Reynolds, S.J. (2007). Fever in rural Ugandan outpatients: a microbiologic survey of causative agents. Presented at the Infectious Diseases Society of America Annual Meeting, October 2007, San Diego California (Abstract 583).Google Scholar
  90. Moore, D.M., Mermin, J., Awor, A., Yip, B., Hogg, R.S. & Montaner, J.S. (2006). Performance of immunologic responses in predicting viral load suppression: implications for monitoring patients in resource-limited settings. Journal of Acquired Immune Deficiency Syndromes, 43, 436–439.PubMedGoogle Scholar
  91. Morris, J.D., Golub, E.T., Mehta, S.H., Jacobson, L.P. & Gange, S.J. (2007). Injection drug use and patterns of highly active antiretroviral therapy use: an analysis of ALIVE, WIHS, and MACS cohorts. AIDS Research and Therapy, 4, 12.PubMedGoogle Scholar
  92. Morse, C.G. & Kovacs, J.A. (2006). Metabolic and skeletal complications of HIV infection: the price of success. Journal of the American Medical Association, 296, 844–854.PubMedGoogle Scholar
  93. Nachega, J.B., Stein, D.M., Lehman, D.A., Hlatshwayo, D., Mothopeng, R., Chaisson, R.E. & Karstaedt, A.S. (2004). Adherence to antiretroviral therapy in HIV-infected adults in Soweto, South Africa. AIDS Research and Human Retroviruses, 20, 1053–1056.PubMedGoogle Scholar
  94. Nacher, M., El Guedj, M., Vaz, T., Nasser, V., Randrianjohany, A., Alvarez, F., Sobesky, M., Magnien, C. & Couppie, P. (2006). Risk factors for follow-up interruption of HIV patients in French Guiana. American Journal of Tropical Medicine and Hygiene, 74, 915–917.PubMedGoogle Scholar
  95. Nakanjako, D., Kamya, M., Daniel, K., Mayanja-Kizza, H., Freers, J., Whalen, C., Katabira, E. (2006). Acceptance of routine testing for HIV among adult patients at the medical emergency unit at a national referral hospital in Kampala, Uganda. AIDS Behavior, 11, 753–758.Google Scholar
  96. Nettles, R.E., Kieffer, T.L., Simmons, R.P., Cofrancesco, J., Jr., Moore, R.D., Gallant, J.E., Persaud, D. & Siliciano, R.F. (2004). Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy. Clinical Infectious Diseases, 39, 1030–1037.PubMedGoogle Scholar
  97. Nunez, M. & Soriano, V. (2005). Hepatotoxicity of antiretrovirals. Drug Safety, 28, 53–66.PubMedGoogle Scholar
  98. Obel, N., Thomsen, H.F., Kronborg, G., Larsen, C.S., Hildebrandt, P.R., Sorensen, H.T. & Gerstoft, J. (2007). Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clinical Infectious Diseases, 44, 1625–1631.PubMedGoogle Scholar
  99. Park, W.G., Bishai, W.R., Chaisson, R.E. & Dorman, S.E. (2002). Performance of the microscopic observation drug susceptibility assay in drug susceptibility testing for Mycobacterium tuberculosis. Journal of Clinical Microbiology, 40, 4750–4752.PubMedGoogle Scholar
  100. Parkin, D.M. (2006). The global health burden of infection-associated cancers in the year 2002. International Journal of Cancer, 118, 3030–3044.Google Scholar
  101. Perez, F., Mukotekwa, T., Miller, A., Orne-Gliemann, J., Glenshaw, M., Chitsike, I. & Dabis, F. (2004). Implementing a rural programme of prevention of mother-to-child transmission of HIV in Zimbabwe: first 18 months of experience. Tropical Medicine and International Health, 9, 774–783.PubMedGoogle Scholar
  102. Pilcher, C.D., Tien, H.C., Eron, J.J., Jr., Vernazza, P.L., Leu, S.Y., Stewart, P.W., Goh, L.E. & Cohen, M.S. (2004). Brief but efficient: acute HIV infection and the sexual transmission of HIV. Journal of Infectious Diseases, 189, 1785–1792.PubMedGoogle Scholar
  103. Quinn, T.C., Wawer, M.J., Sewankambo, N., Serwadda, D., Li, C., Wabwire-Mangen, F., Meehan, M.O., Lutalo, T. & Gray, R.H. (2000). Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. New England Journal of Medicine, 342, 921–929.PubMedGoogle Scholar
  104. Reynolds, S. J. unpublished data on Structured-Treatment Interruption Trial in Uganda.Google Scholar
  105. Rodriguez, B., Sethi, A.K., Cheruvu, V.K., Mackay, W., Bosch, R.J., Kitahata, M., Boswell, S.L., Mathews, W.C., Bangsberg, D.R., Martin, J., Whalen, C.C., Sieg, S., Yadavalli, S., Deeks, S.G. & Lederman, M.M. (2006). Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. Journal of the American Medical Association, 296, 1498–1506.PubMedGoogle Scholar
  106. Ross, L., Lim, M.L., Liao, Q., Wine, B., Rodriguez, A.E., Weinberg, W. & Shaefer, M. (2007). Prevalence of antiretroviral drug resistance and resistance-associated mutations in antiretroviral therapy-naive HIV-infected individuals from 40 United States cities. HIV Clinical Trials, 8, 1–8.PubMedGoogle Scholar
  107. Sanne, I., Mommeja-Marin, H., Hinkle, J., Bartlett, J.A., Lederman, M.M., Maartens, G., Wakeford, C., Shaw, A., Quinn, J., Gish, R.G. & Rousseau, F. (2005). Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. Journal of Infectious Diseases, 191, 825–829.PubMedGoogle Scholar
  108. Schutz, C., Stead, D., Meintjies, G., Rebe, K., Boulle, A. & Osler, M. (2007). Trends in the presentation and mortality of severe hyperlactatemia at a public sector referral hospital in Cape Town. Presented at the 3rd South African AIDS Conference, June 2007, Durban, South Africa.Google Scholar
  109. Sherr, L., Lopman, B., Kakowa, M., Dube, S., Chawira, G., Nyamukapa, C., Oberzaucher, N., Cremin, I. & Gregson, S. (2007). Voluntary HIV testing in rural Zimbabwe. Presented at the 3rd South African AIDS Conference, June 2007, Durban, South Africa.Google Scholar
  110. Shisana, O., Rehle, T., Simbayi, L.C., Parker, W., Zuma, K., Bhana, A., Connolly, C., Jooste, S., Pillay, V. & et al. (2005). South African national HIV prevalence, HIV incidence, behaviour and communication survey. HSRC Press, Cape Town.Google Scholar
  111. Sirisanthana, T. (2001). Penicillium marneffei infection in patients with AIDS. Emerging Infectious Diseases, 7, 561.PubMedGoogle Scholar
  112. SMART Study Group, El-Sadr, W.M., Lundgren, J.D., Neaton, J. D., Gordin, F., Abrams, D., Artuino, R.C., Babiker, A., Burman, W., Clumeck, N., Cohen, C.J., Cohn, D., Cooper, D., Darbyshire, J., Emery S., Fatkenheuer, G., Gazzard, B., Grund, B., Hoy, J., Klingman, K., Losso, M., Markowitz, N., Neuhaus, J., Phillips A. & Rappoport, C. (2006). CD4+ guided interruption of antiretroviral treatment. New England Journal of Medicine, 355, 2283–2296.PubMedGoogle Scholar
  113. Spacek, L.A., Gray, R.H., Wawer, M.J., Sewankambo, N.K., Serwadda, D., Wabwire-Mangen, F., Kiwanuka, N., Kigozi, G., Nalugoda, F. & Quinn, T.C. (2006a). Clinical illness as a marker for initiation of HIV antiretroviral therapy in a rural setting, Rakai, Uganda. International Journal of STD & AIDS, 17, 116–120.Google Scholar
  114. Spacek, L.A., Shihab, H.M., Kamya, M.R., Mwesigire, D., Ronald, A., Mayanja, H., Moore, R.D., Bates, M. & Quinn, T.C. (2006b). Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda. Clinical Infectious Diseases, 42, 252–259.Google Scholar
  115. Stein K., Astemborski J., Mehta S., Vlahov D., Galai N. & Kirk G. (2007). Trends and risk factors for community-acquired penumonia among HIV-infected and HIV-uninfected intravenous drug users. Presented at the XVI International AIDS Conference, August 2006, Toronto, Canada (Abstract MOAB0303).Google Scholar
  116. Sterling, T.R., Vlahov, D., Astemborski, J., Hoover, D.R., Margolick, J.B. & Quinn, T.C. (2001). Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. New England Journal of Medicine, 344, 720–725.PubMedGoogle Scholar
  117. Stringer, J.S., Zulu, I., Levy, J., Stringer, E.M., Mwango, A., Chi, B.H., Mtonga, V., Reid, S., Cantrell, R.A., Bulterys, M., Saag, M.S., Marlink, R.G., Mwinga, A., Ellerbrock, T.V. & Sinkala, M. (2006). Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. Journal of the American Medical Association, 296, 782–793.PubMedGoogle Scholar
  118. Sturmer, M., Dauer, B., Moesch, M., Haberl, A., Mueller, A., Locher, L., Knecht, G., Hanke, N., Doerr, H.W. & Staszewski, S. (2007). Evolution of resistance mutations during low-level viral replication in HIV-1-infected patients treated with zidovudine/lamivudine/abacavir as a first-line regimen. Antiviral Therapy, 12, 25–30.PubMedGoogle Scholar
  119. Sungkanuparph, S., Manosuthi, W., Kiertiburanakul, S., Piyavong, B., Chumpathat, N. & Chantratita, W. (2007). Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clinical Infectious Diseases, 44, 447–452.PubMedGoogle Scholar
  120. Temmerman, M., Quaghebeur, A., Mwanyumba, F. & Mandaliya, K. (2003). Mother-to-child HIV transmission in resource poor settings: how to improve coverage? AIDS, 17, 1239–1242.PubMedGoogle Scholar
  121. Van Cutsem, V., Cohen, K., Bedelu, M., Sarunchuk, P., Hilderbrand, K., Coetzee, D. & Boulle, A. (2007). TB/HIV co-infected patients on rifampicin containing treatment have equivalent ART treatment outcomes, and concurrent use of nevirapine is not associated with increased hepatotoxicity. Presented at the 3rd IAS Conference on HIV Pathogenesis and Treatment, July 2005, Rio De Janeiro, Brazil (Abstract WePp0303).Google Scholar
  122. van Oosterhout, J.J., Bodasing, N., Kumwenda, J.J., Nyirenda, C., Mallewa, J., Cleary, P.R., de Baar, M.P., Schuurman, R., Burger, D.M. & Zijlstra, E.E. (2005). Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi. Tropical Medicine and International Health, 10, 464–470.PubMedGoogle Scholar
  123. van Oosterhout, J.J., Laufer, M.K., Perez, M.A., Graham, S.M., Chimbiya, N., Thesing, P.C., varez-Martinez, M.J., Wilson, P.E., Chagomerana, M., Zijlstra, E.E., Taylor, T.E., Plowe, C.V. & Meshnick, S.R. (2007). Pneumocystis pneumonia in HIV-positive adults, Malawi. Emerging Infectious Diseases, 13, 325–328.PubMedGoogle Scholar
  124. Venter, F. (2007). Make HIV tests compulsory for South Africans. Sunday Times, Johannesburg, June 3.Google Scholar
  125. Walensky, R.P., Paltiel, A.D., Losina, E., Mercincavage, L.M., Schackman, B.R., Sax, P.E., Weinstein, M.C. & Freedberg, K.A. (2006). The survival benefits of AIDS treatment in the United States. Journal of Infectious Diseases, 194, 11–19.PubMedGoogle Scholar
  126. Wawer ,M.J., Gray, R.H., Sewankambo, N.K., Serwadda, D., Li, X., Laeyendecker, O., Kiwanuka, N., Kigozi, G., Kiddugavu, M., Lutalo, T., Nalugoda, F., Wabwire-Mangen, F., Meehan, M.P. & Quinn, T.C. (2005). Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. Journal of Infectious Diseases, 191, 1403–1409.PubMedGoogle Scholar
  127. Whalen, C.C., Johnson, J.L., Okwera, A., Hom, D.L., Huebner, R., Mugyenyi, P., Mugerwa, R.D. & Ellner, J.J. (1997). A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. New England Journal of Medicine, 337, 801–808.PubMedGoogle Scholar
  128. Wit, F., Kesselring, A., Gras, L., Richter, C., van der Ende, M., Brinkman, K., Lange, J., de Wolf, F. & Reiss, P. (2007). Incidence of nevirapine-associated hypersensitivity reactions is different in patients with prior treatment experience compared to treatment-naïve patients: the ATHENA cohort study. Presented at the 4th IAS Conference, July 2007, Sydney, Australia (Abstract MOPEB008).Google Scholar
  129. World Health Organization (2006a). Global Health Report: Working Together for Health. (Accessed November 15, 2007); www.who.int/whr/2006/en/index.html/
  130. World Health Organization (2006b). Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: towards universal access. www.who.int/hiv/pub/guidelines (8/7/2006). World Health Organization, Geneva.
  131. World Health Organization (2007). HIV testing and counselling. (Accessed November 15, 2007); www.who.int/hiv/topics/vct/en/index.html.
  132. Wood, R., Middelkoop, K., Myer, L., Grant, A.D., Whitelaw, A., Lawn, S.D., Kaplan, G., Huebner, R., McIntyre, J. & Bekker, L.G. (2007). Undiagnosed tuberculosis in a community with high HIV prevalence: implications for tuberculosis control. American Journal of Respiratory and Critical Care Medicine, 175, 87–93.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Christopher J. Hoffmann
    • 1
  • Lisa A. Mills
    • 1
  • Joel E. Gallant
    • 1
  1. 1.Johns Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations